Price movement over the last 24 hours
Agilent Technologies Inc vs Dell Technologies Inc — how do they compare? Agilent Technologies Inc trades at $128.64 (market cap $37.04B), while Dell Technologies Inc trades at $418.01 (market cap $269.62B). The key difference: Dell Technologies Inc is far larger — about 7.3× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays the higher dividend (0.78%). Which is the better fit depends on your goals.
| A | DELL | |
|---|---|---|
Market Cap | $37.04B | $269.62B |
Sector | Health | Technology |
52-Week High | $157.20 | $466.02 |
52-Week Low | $110.24 | $111.10 |
Enterprise Value | $38.59B | $289.21B |
Dividend Yield | 0.78% | 0.6% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Dell Technologies trades at $416.98, up 5.75% in the last 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $484.28. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $4.86 surpassing the $2.96 estimate. The company shows strong revenue growth projections to $134 billion in 2026 and benefits from AI server demand, though net cash flow was negative $3.69 billion in 2025.
The outlook for Dell is positive, driven by AI infrastructure dominance and expanding profit margins, but risks include supply constraints, competitive pressures, and negative shareholder equity. With 57.8% of analysts rating it a buy, the stock offers growth potential, yet investors should weigh execution risks against the robust AI-driven revenue backlog.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →